Budget 2014

Presenting Sponsor : JK TyrePowered By : LG OLED TV
You are here:HomeBudgetPharma

Pharma

  • Biocon to Invest 10% of Biopharma Revenues on R&D

    Biocon to Invest 10% of Biopharma Revenues on R&D

    The company, which is pursuing R&D in both novel biologics as well as biosimilars (generic versions of biologic drugs), in various stages of trials, had spent around Rs 131 crore on R&D in the previous fiscal year which was 6 per cent of biopharma sales.

  • Divis Labs Plans to Invest Rs 500 Crore to Set Up Plant

    Divis Labs Plans to Invest Rs 500 Crore to Set Up Plant

    Divis Laboratories Ltd plans to invest Rs 500 crore in Andhra Pradesh to set up its third manufacturing facility as it looks to augment its production capacity.

  • Price Performance of Pharma Stocks Other Stories
  • Sun Pharma Wins US Nod to Buy Ranbaxy

    Sun Pharma Wins US Nod to Buy Ranbaxy

    Sun Pharmaceutical Industries Ltd has won US approval to buy Ranbaxy Laboratories Ltd on condition that it will sell its interest in a generic antibacterial medicine, the US Federal Trade Commission said on Friday.

  • USFDA Continues Nod for Strides Oral Dosage Facility

    USFDA Continues Nod for Strides Oral Dosage Facility

    "The company's Oral Dosage Facility (KRS Gardens) at Bangalore has been found acceptable by the United States Food and Drug Administration (US FDA)," Strides Arcolab said in a filing to BSE.

  • Ranbaxy Forfeits 180 Days Exclusivity for Stomach Drugs

    Ranbaxy Forfeits 180 Days Exclusivity for Stomach Drugs

    Drug major Ranbaxy on Tuesday said that the US Food and Drug Administration or FDA has "determined" that the Indian drug manufacturer has forfeited its 180 days exclusivity for stomach and esophagus problems treatment tablets.

  • Aurobindo Pharma to Raise $350 Million Through QIP

    Aurobindo Pharma to Raise $350 Million Through QIP

    The board had earlier constituted a securities issue committee comprising of five board members, including two independent directors, for issue of securities.

  • Aurobindo, Actavis Recall Gabapentin Capsules

    Aurobindo, Actavis Recall Gabapentin Capsules

    According to notification by the US Food and Drug Administration (USFDA), the Indian firm's arm Aurobindo Pharma USA Inc has initiated a Class II nation wide recall. Each bottle contains 100 capsules of 300 mg.

  • Novartis to Close Manufacturing Plant in Puerto Rico by 2019

    Novartis to Close Manufacturing Plant in Puerto Rico by 2019

    Novartis AG is closing its manufacturing plant in Puerto Rico as part of a major overhaul of its business.

  • Cipla Promoters Firm Buys Out Minority Investors in Okasa

    Cipla Promoters Firm Buys Out Minority Investors in Okasa

    Hamsons, a firm owned by the promoter family of pharmaceuticals major Cipla, has bought out the remaining 21 per cent equity owned by minority shareholders in Satara-based Okasa Pharma for an undisclosed amount, completing the process it started last September.

  • Gilead's Hepatitis C Drug Patent Request Rejected

    Gilead's Hepatitis C Drug Patent Request Rejected

    India's patent office has rejected an application from US-based Gilead Sciences Inc for its hepatitis C drug Sovaldi, paving the way for local drug makers to launch cheaper generic versions of the $1,000-a-pill medicine.

  • Novartis Gets Court Notice on Cipla Plea

    Novartis Gets Court Notice on Cipla Plea

    A bench of justices Badar Durrez Ahmed and Sanjeev Sachdeva, however, refused to pass any interim order to allow Cipla to manufacture its Indacaterol-based drug saying, it will give an early hearing to the matter.

  • Court Order Restraining Drug Sale Disappointing: Cipla

    Court Order Restraining Drug Sale Disappointing: Cipla

    Cipla has expressed disappointment over a Delhi High Court order restraining the drug maker from manufacturing and selling any medicine containing 'Indacaterol', saying that the interim verdict would deny patients access to the drugs they need.

  • Cipla Restrained From Selling Obstructive Pulmonary Disease Treatment Drug

    Cipla Restrained From Selling Obstructive Pulmonary Disease Treatment Drug

    The Delhi High Court on Friday temporarily restrained Cipla from manufacturing, importing or selling any drug containing the chemical Indacaterol which is used for treatment of chronic obstructive pulmonary disease (COPD) till it obtains a compulsory licence for the medicine.

  • Cadila Recalls 19,536 Bottles of Cough Treatment Drug in US

    Cadila Recalls 19,536 Bottles of Cough Treatment Drug in US

    Drug firm Cadila Healthcare is voluntarily recalling 19,536 bottles of benzonatate capsules, used to treat cough, in the US due to "wet and/or leaking capsules".

  • Wockhardt, Cadila, Hospira Recall Drugs in US

    Wockhardt, Cadila, Hospira Recall Drugs in US

    Drug firms Wockhardt, Cadila Healthcare and Hospira are voluntarily recalling certain lots of drugs in the US, according to the US Food and Drug Administration (FDA).

  • Lupin Gets Regulatory Nod to Market HIV Drug in US

    Lupin Gets Regulatory Nod to Market HIV Drug in US

    Drug firm Lupin has received a tentative approval from the US Food and Drug Administration (FDA) to market a generic version of Prezista tablets used in treating HIV infection.

  • 2014: Pharma Deals Worth Billions, Fines Worth Millions

    2014: Pharma Deals Worth Billions, Fines Worth Millions

    It has been a year of bitter medicine for Indian pharmaceutical companies with fines worth millions of dollars imposed by various foreign regulators, even as they stitched together deals worth billions of dollars, including a high profile merger between Sun Pharma and Ranbaxy.

  • Lupin Gets US Regulator's Nod for HIV Drug

    Lupin Gets US Regulator's Nod for HIV Drug

    Drug major Lupin has received approval of the US Food and Drug Administration (FDA) to market a generic version of ViiV Healthcare's 'Epivir' tablets, used in treating HIV infection, in the American market. Shares in Lupin rose nearly 1 per cent during the day.

  • Medical Devices Sector Welcomes 100% FDI

    Medical Devices Sector Welcomes 100% FDI

    Medical device makers on Wednesday welcomed the government's decision to allow up to 100 per cent foreign direct investment or FDI in the sector under automatic route, saying the move would boost technology inflow and manufacturing.

  • FDI Norms Eased for Medical Device Makers

    FDI Norms Eased for Medical Device Makers

    The government has made it easier for foreigners to fully own existing medical device makers in India, in a bid to boost investment in the $7-billion sector.

Advertisement

Stock Watch

Advertisement

Market Data provided by © Accord Fintech.
© Copyright NDTV Convergence Limited 2015. All rights reserved.